Palvella Therapeutics appoints David Osborne as chief innovation officer

WAYNE, Pa. - Palvella Therapeutics, Inc. (NASDAQ:PVLA) has appointed David W. Osborne, Ph.D. as Chief Innovation Officer, effective immediately, the clinical-stage biopharmaceutical company announced Wednesday.

Dr. Osborne, who co-founded Arcutis Biotherapeutics and served as its Chief Technical Officer, brings over 25 years of experience in developing topical therapies for skin diseases. He has contributed to the development of three dozen topical therapies, including ZORYVE (roflumilast) cream and foam. According to InvestingPro data, Arcutis has shown impressive performance with a 46% stock return over the past year and maintains strong gross profit margins of 89%.

In his new role, Osborne will lead Palvella’s early-stage R&D pipeline, with a focus on expanding the company’s proprietary QTORIN platform, which is designed to create targeted topical therapies for rare genetic skin diseases.

"Having spent over 25 years working in formulation science and translational innovation, I have seen firsthand how thoughtful, patient-centered drug development can make a profound impact," said Dr. Osborne in the company statement.

Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently being evaluated in a Phase 3 clinical trial for microcystic lymphatic malformations and a Phase 2 trial for cutaneous venous malformations. The company plans to announce a second QTORIN product candidate by the end of 2025.

"His track record of developing innovative FDA-approved medicines, combined with his deep expertise in novel topical drug formulation, will be invaluable," said Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics.

Palvella focuses on developing therapies for serious, rare genetic skin diseases for which there are currently no FDA-approved treatments. The information in this article is based on a press release from the company.

In other recent news, Arcutis Biotherapeutics reported its financial results for the second quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company achieved an EPS of -$0.13, which was better than the anticipated -$0.17. Additionally, Arcutis reported revenue of $81.5 million, exceeding expectations by 11.26%. These results highlight the company’s ability to outperform market predictions. While no information on mergers or acquisitions was provided, the positive earnings report is a significant development for investors. There were no mentions of analyst upgrades or downgrades in the recent news. Arcutis’s financial performance is a noteworthy point of interest for stakeholders. These developments reflect the company’s current financial trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.